KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Non-Current Deffered Revenue (2016 - 2021)

Historic Non-Current Deffered Revenue for Biolife Solutions (BLFS) over the last 11 years, with Q1 2021 value amounting to $64000.0.

  • Biolife Solutions' Non-Current Deffered Revenue changed N/A to $64000.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $64000.0, marking a year-over-year change of. This contributed to the annual value of $71000.0 for FY2020, which is N/A changed from last year.
  • Biolife Solutions' Non-Current Deffered Revenue amounted to $64000.0 in Q1 2021.
  • Over the past 5 years, Biolife Solutions' Non-Current Deffered Revenue peaked at $492000.0 during Q4 2017, and registered a low of -$63836.0 during Q3 2017.
  • Its 4-year average for Non-Current Deffered Revenue is $177300.2, with a median of $71000.0 in 2020.
  • Within the past 5 years, the most significant YoY rise in Biolife Solutions' Non-Current Deffered Revenue was 165783.34% (2017), while the steepest drop was 57232.1% (2017).
  • Biolife Solutions' Non-Current Deffered Revenue (Quarter) stood at $492000.0 in 2017, then decreased by 29.07% to $349000.0 in 2018, then tumbled by 79.66% to $71000.0 in 2020, then decreased by 9.86% to $64000.0 in 2021.
  • Its Non-Current Deffered Revenue was $64000.0 in Q1 2021, compared to $71000.0 in Q4 2020 and $349000.0 in Q4 2018.